Virtus LifeSci Biotech Clinical Trials ETF Rating $43.02 -0.61 (-1.40%) As of 06/16/2026 04:10 PM Eastern Add Compare Share Share Ratings Stock AnalysisChartDividendHoldingsRatingsShort InterestBuy This Stock Virtus LifeSci Biotech Clinical Trials ETF Aggregate Rating and Price Target (2026)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.BBC Aggregate RatingModerate Buy 2.77Holdings in BBC have an aggregate rating of Moderate Buy based on 301 analyst ratings issued in the past year covering 25 companies (35.4% of the portfolio).BBC Aggregate Price Target$43.02High Prediction$43.02Average Prediction$43.02Low Prediction$43.02Holdings in BBC have an aggregate price target of $43.02 and a range of $43.02 to $43.02 covering 25 companies (35.4% of the portfolio).BBC Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy5 Buy rating(s)Moderate Buy18 Moderate Buy rating(s)Hold2 Hold rating(s)Reduce0 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by Virtus LifeSci Biotech Clinical Trials ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 25 BBC Holdings ExportWeight In ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings2.69%ERASErasca$13.38-7.3%2.1863 of 5 stars2.60$20.11 50.3%10Trending News1.91%RZLTRezolute$4.57+5.5%3.3353 of 5 stars2.64$9.38 105.1%11Analyst Downgrade1.77%SYRESpyre Therapeutics$83.41-0.2%1.9301 of 5 stars3.00$94.17 12.9%13News CoverageAnalyst Forecast1.75%TNGXTango Therapeutics$32.16-2.2%2.1283 of 5 stars2.71$38.42 19.5%141.66%ELVNEnliven Therapeutics$42.55+0.4%2.7779 of 5 stars2.83$63.40 49.0%6High Trading Volume1.61%ORKAOruka Therapeutics$67.71-1.7%2.4764 of 5 stars2.82$131.30 93.9%11News CoverageInsider Trade1.54%DNTHDianthus Therapeutics$78.88-4.4%2.3574 of 5 stars2.93$117.82 49.4%141.53%RVMDRevolution Medicines$156.58-2.2%1.8043 of 5 stars3.00$123.72 -21.0%22Positive News1.52%DFTXDefinium Therapeutics$24.16+1.6%2.9125 of 5 stars3.00$37.92 57.0%15Analyst Forecast1.50%LQDALiquidia$68.01-5.3%3.0109 of 5 stars2.90$60.29 -11.4%10Insider Trade1.45%CMPSCompass Pathways$11.49-2.5%3.2777 of 5 stars2.93$21.36 85.9%141.36%RLAYRelay Therapeutics$15.05+0.6%3.1334 of 5 stars3.00$23.30 54.8%111.34%ALMSAlumis$22.32-3.0%3.0121 of 5 stars2.83$40.30 80.6%121.33%GHRSGH Research$19.98-1.9%3.1064 of 5 stars2.73$40.38 102.1%11Positive News1.25%ABCLAbCellera Biologics$5.09-3.2%1.9805 of 5 stars2.67$7.80 53.2%61.22%EWTXEdgewise Therapeutics$33.95-3.6%2.5983 of 5 stars2.78$45.00 32.5%9News CoverageAnalyst ForecastHigh Trading Volume1.21%NTLAIntellia Therapeutics$14.55-2.5%3.186 of 5 stars2.35$20.46 40.6%23Analyst Forecast1.21%CNTACentessa Pharmaceuticals$39.750.0%1.7967 of 5 stars2.21$41.33 4.0%14Positive News1.19%TECXTectonic Therapeutic$30.01+2.1%2.8564 of 5 stars3.00$79.40 164.6%71.10%QUREuniQure$26.99-3.2%2.0437 of 5 stars2.53$42.83 58.7%171.07%CRVSCorvus Pharmaceuticals$11.74-1.3%3.9248 of 5 stars2.71$33.33 183.9%7Insider Trade1.06%CGONCG Oncology$60.28+1.2%2.8228 of 5 stars2.71$81.73 35.6%14Insider Trade1.05%KODKodiak Sciences$32.94-3.3%2.4518 of 5 stars2.63$42.14 27.9%81.04%PHVSPharvaris$31.46-0.3%3.2294 of 5 stars2.69$49.18 56.3%13Analyst Forecast1.04%VIRVir Biotechnology$8.611.9352 of 5 stars2.89$20.88 142.5%9 This page (NYSEARCA:BBC) was last updated on 6/17/2026 by MarketBeat.com Staff. From Our PartnersIs SpaceX really worth 1.78 Trillion?With SpaceX approaching a near-$2 trillion valuation, most investors are focused on the IPO itself - but analy...InvestPub | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredSpaceX is chump change compared to Elon’s $20T ‘iPhone’Early Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider source...StocksToTrade | SponsoredTrump just signed itA recent policy development is drawing attention from income-focused investors. According to one analyst, c...Investors Alley | SponsoredThis is the worst news for stocks in 50 yearsGoldman Sachs and Morgan Stanley are issuing a rare warning: what's ahead for U.S. stocks could be the worst e...TradeSmith | SponsoredPorter flew 3,300 miles to investigate this systemPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredElon’s new "tollbooth"The SpaceX IPO was valued at $1.75 trillion. But one analyst says fighting over those shares may be the wrong ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Virtus LifeSci Biotech Clinical Trials ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Virtus LifeSci Biotech Clinical Trials ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
